Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Announces Agreement with Agiomix FZ-LLC for Target Selector Liquid Biopsy Kits
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC ), a leading commercial provider of liquid biopsy solutions, announces that it has entered into an agreement with Agiomix FZ-LLC ("Agiomix"), a provider of genomics sample and bioinformatics services to customers around the
View HTML
Toggle Summary Published Case Series Indicates the Ability of Biocept's Liquid Biopsy Testing to Identify Actionable Biomarkers When Tissue Biopsy Is Unsuccessful
Peer-reviewed article in journal, Clinics in Oncology, further supports the clinical utility of Biocept's Target Selector™ platform to aid physicians in the selection of targeted therapy for patients with lung cancer SAN DIEGO , Feb. 5, 2019 /PRNewswire/ --  Biocept, Inc.
View HTML
Toggle Summary Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA
Target Selector™ kits are research-use-only (RUO) and designed to enable laboratories around the world to leverage Biocept's patented assay technology to perform cutting-edge liquid biopsy testing SAN DIEGO , Jan. 28, 2019 /PRNewswire/ --  Biocept, Inc.
View HTML
Toggle Summary Biocept Announces Pricing of $2.2 Million Registered Direct Offering
SAN DIEGO , Jan. 18, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
View HTML
Toggle Summary Biocept and Prognos Enter Into Partnership to Apply Artificial Intelligence in Order to Help Pharmaceutical and Life Sciences Companies Optimize Commercialization of Biomarker-Targeted Therapies in Oncology
Partnership enables Biocept's data monetization strategy and enhances Prognos' repository of more than 20 billion laboratory records to predict disease earlier SAN DIEGO , Dec. 18, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to
View HTML
Toggle Summary Biocept Reports Third Quarter 2018 Financial Results
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 13, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
View HTML
Toggle Summary Biocept to Release Third Quarter 2018 Financial Results and Host Investor Conference Call on November 13, 2018
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
View HTML
Toggle Summary Biocept Announces New Executive Hires to its Sales and Marketing Organization
Appoints Scott Nicholson as Vice President of National Sales - US; Cory Dunn as Vice President of Marketing SAN DIEGO , Nov. 5, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable
View HTML
Toggle Summary Biocept to Present at the Dawson James Securities Small Cap Growth Conference on October 30
SAN DIEGO , Oct. 23, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept Obtains Japanese Patent for its Target Selector Oncogene Mutation Enrichment and Detection Platform
Expands intellectual property to 30 issued patents globally for highly sensitive methods of detecting cancer biomarkers SAN DIEGO , Oct. 18, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically
View HTML